Bigal will be responsible for general medical governance and patient safety oversight relating to all Purdue products in development and in the market. He will also become part of the senior leadership team that addresses the scientific and medical aspects of the company's product portfolio with government agencies, including the US Food and Drug Administration.
Bigal brings more than 12 years of pharmaceutical experience spanning research and development, clinical operations and innovations, and scientific affairs. He most recently served as chief scientific officer at Teva Pharmaceuticals. Prior to that he served as CMO and head of the clinical development organization, in which he oversaw innovative clinical development (Phases 1 to 3) across all specialty areas. Before joining Teva, Bigal was CMO at Labrys Biologics, Inc.
Bigal holds a Medical Doctorate degree from the College of Medicine at the University of São Paulo, Brazil, where he also obtained a Masters in Science and a PhD in Neurosciences. He completed his post-doctoral research at the New England Center for Headache in Stamford, Conn.
Privately-held Purdue Pharma is part of a network of independent associated companies dedicated to providing patients and providers with innovative medicines. The company's leadership and employees are committed to serving healthcare professionals, patients and caregivers by providing quality products and educational resources.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business